GlassScriptPhysician profile
Nicole Johnson
NPI 1982291530
$5,389.87
in general payments reported to CMS, 2019-2025
19 companies · $888 in 2025
The $888 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $1,469 · 2023: $872 · 2024: $876 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.38 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.33 | 2021-2025 | |
| Lundbeck LLC | $890.84 | 2021-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $777.77 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $575.49 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $543.83 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $279.94 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $196.59 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $190.29 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $158.75 | 2021-2022 | |
| Axsome Therapeutics, INC. | $137.51 | 2023-2025 | Auvelity |
| Livanova USA, INC. | $98.40 | 2021-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Vanda Pharmaceuticals INC. | $87.08 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $57.42 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $52.55 | 2022-2023 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $52.37 | 2024-2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $31.78 | 2022-2023 | Perseris |
| Noven Therapeutics, LLC | $30.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.36 | 2022 | |
| Bausch Health US, LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.